Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease

Abstract Background The incidence of inflammatory bowel disease (IBD) is increasing worldwide, emphasizing the need of relevant models, as dogs spontaneously affected by IBD may be, for better knowledge of the disease’s physiopathology. Methods We studied 22 client-owned dogs suffering from IBD without protein loss and 14 control dogs. Biopsies were obtained from the duodenum, ileum, and colon. Inflammatory grade was assessed by histopathology, immunohistochemistry, and chemokine analysis. The expression of Toll-like receptors (TLR) in mucosa was immunohistochemically evaluated. Antibody levels against bacterial ligands (lipopolysaccharide [LPS] and flagellin) were measured in sera using enzyme-linked immunoassay. Results Dogs with IBD showed low to severe clinical disease. Histopathologically, the gut of dogs with IBD did not exhibit significant alterations compared with controls except in the colon. The number of CD3+ T lymphocytes was decreased in the ileum and colon of dogs with IBD compared with controls, whereas the numbers of Foxp3+, CD20+, and CD204+ cells were similar in the 2 groups. Three chemokines, but no cytokines, were detected at the protein level in the mucosa, and the disease poorly affected their tissue concentrations. Dogs with IBD exhibited higher serum reactivity against LPS and flagellin than controls but similar immunoreactivity against the receptors TLR4 and TLR5. In addition, TLR2 and TLR9 showed similar expression patterns in both groups of dogs. Conclusions Our data described dysregulated immune responses in dogs affected by IBD without protein loss. Despite fairly homogeneous dog cohorts, we were still faced with interindividual variability, and new studies with larger cohorts are needed to validate the dog as a model.

Download Full-text

Takayasu’s arteritis with skin manifestations in a patient with inflammatory bowel disease: coincidence or concurrence?

Clinical Rheumatology ◽

10.1007/s10067-006-0233-2 ◽

2006 ◽

Vol 26 (6) ◽

pp. 996-998 ◽

Cited By ~ 8

Author(s):

Misbah Baqir ◽

Mohammed Haris Umer Usman ◽

Humaira N. Adenwalla ◽

Saqib Aziz ◽

Fazle Noor ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Takayasu’S Arteritis ◽

Takayasu's Arteritis ◽

Skin Manifestations ◽

Inflammatory Bowel

Download Full-text

Blood microRNA (miRNA) Expression Patterns Can Identify Inflammatory Bowel Disease (IBD) Patients with Dysplasia and Cancer: 2011 ACG Presidential Poster

The American Journal of Gastroenterology ◽

10.14309/00000434-201110002-01212 ◽

2011 ◽

Vol 106 ◽

pp. S457

Author(s):

Francis Farraye ◽

Michelle Brown ◽

Sharat Singh ◽

Fred Princen

Keyword(s):

Inflammatory Bowel Disease ◽

Mirna Expression ◽

Bowel Disease ◽

Expression Patterns ◽

Inflammatory Bowel

Download Full-text

Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study

PLoS ONE ◽

10.1371/journal.pone.0210436 ◽

2019 ◽

Vol 14 (1) ◽

pp. e0210436 ◽

Cited By ~ 9

Author(s):

Nina Roth ◽

Luc Biedermann ◽

Nicolas Fournier ◽

Matthias Butter ◽

Stephan R. Vavricka ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Cohort Study ◽

Bowel Disease ◽

Skin Manifestations ◽

Inflammatory Bowel

Download Full-text

Skin Manifestations of Inflammatory Bowel Disease

Clinical Reviews in Allergy & Immunology ◽

10.1007/s12016-017-8617-4 ◽

2017 ◽

Vol 53 (3) ◽

pp. 413-427 ◽

Cited By ~ 36

Author(s):

Thomas Greuter ◽

Alexander Navarini ◽

Stephan R. Vavricka

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Skin Manifestations ◽

Inflammatory Bowel

Download Full-text

Inflammatory Bowel Disease–associated GP2 Autoantibodies Inhibit Mucosal Immune Response to Adherent-invasive Bacteria

Inflammatory Bowel Diseases ◽

10.1093/ibd/izaa069 ◽

2020 ◽

Vol 26 (12) ◽

pp. 1856-1868

Author(s):

Stefanie Derer ◽

Ann-Kathrin Brethack ◽

Carlotta Pietsch ◽

Sebastian T Jendrek ◽

Thomas Nitzsche ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Intestinal Inflammation ◽

Ex Vivo ◽

Expression Patterns ◽

Mucosal Immune Response ◽

Disease Manifestation ◽

Inflammatory Bowel

Abstract Adherent-invasive Escherichia coli have been suggested to play a pivotal role within the pathophysiology of inflammatory bowel disease (IBD). Autoantibodies against distinct splicing variants of glycoprotein 2 (GP2), an intestinal receptor of the bacterial adhesin FimH, frequently occur in IBD patients. Hence, we aimed to functionally characterize GP2-directed autoantibodies as a putative part of IBD’s pathophysiology. Ex vivo, GP2-splicing variant 4 (GP2#4) but not variant 2 was expressed on intestinal M or L cells with elevated expression patterns in IBD patients. The GP2#4 expression was induced in vitro by tumor necrosis factor (TNF)-α. The IBD-associated GP2 autoantibodies inhibited FimH binding to GP2#4 and were decreased in anti-TNFα-treated Crohn’s disease patients with ileocolonic disease manifestation. In vivo, mice immunized against GP2 before infection with adherent-invasive bacteria displayed exacerbated intestinal inflammation. In summary, autoimmunity against intestinal expressed GP2#4 results in enhanced attachment of flagellated bacteria to the intestinal epithelium and thereby may drive IBD’s pathophysiology.

Download Full-text

P459 Expression of SerpinE1, a potential new disease activity marker, reflects therapeutic response in Inflammatory Bowel Disease

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjab076.812 ◽

2021 ◽

Vol 15 (Supplement_1) ◽

pp. S453-S453

Author(s):

B Jójrt ◽

T Molnár ◽

V Szabó ◽

Á Varga ◽

T Resál ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Disease Activity ◽

Bowel Disease ◽

Healthy Subjects ◽

Expression Patterns ◽

Invasive Disease ◽

Gene Expressions ◽

Inflammatory Bowel ◽

Active Disease ◽

Control Samples

Abstract Background Inflammatory Bowel Disease (IBD) occurs as a consequence of abnormal immune response generating unbalance between pro- and anti-inflammatory signalling. Analysis of cytokine profiles in view of different cytokine targeting or immunosuppressive therapy may open up new therapeutic targets and may reveal biological profiles that distinguish responders from non-responders before initiating therapy. The aim of present study was to determine cytokine profile of IBD patients and identify cytokines with predictive potential. Methods IBD patients with clinically active disease were enrolled in study. Blood and biopsy samples were obtained from 22 IBD patients and 5 healthy controls. Biopsies were taken from inflamed and non-inflamed part of colon of IBD patients. Total protein and mRNA were isolated from biopsy samples. Cytokine Array was used to analyse cytokine expression patterns. Serum and mucosal SerpinE1 levels were measured by ELISA and qRT-PCR. Results In samples from IBD patients, remarkable discrimination between inflamed, or non-inflamed areas was observed, whereas no pro-inflammatory cytokines were detected in control samples. SerpinE1 was presented in every inflamed biopsy samples, which was analyzed in more details. Mucosal expression of SerpinE1 differed significantly in healthy subjects compared to IBD patients with active disease (0 vs 24.06 pg/mg, p=0.02). After therapy induction a remarkable decrease was observed in the mucosal SerpinE1 concentration in responders (45.5 vs 9.7 pg/mg, p=0.02) versus non-responders (45 vs 61.2 pg/mg, p=0.3). Moreover, mean value of mucosal SerpinE1 did not differ significantly in healthy subjects compared to responders (5.7 vs. 0 pg/mg, p=0.12). In non-responders the fold changes of SerpinE1 gene expressions were significantly (p=0.001) higher than in responders. Lowest expression of SerpinE1 gene was measured in control samples, whereas the highest in untreated, inflamed biopsy samples. Serum and mucosal SerpinE1 concentrations were significantly higher in patients with active disease compared to inactive (tissue: 5 vs 47.4 pg/mg, p=0.00003; serum: 22.4 vs 25.94 mg/ml, p=0.022). Correlation analysis revealed that serum SerpinE1 correlates with disease activity (p<0,01, cut-off value: 22 mg/ml, sensitivity=80%, specificity=60%, accuracy=74%), whereas no correlation was observed between the mucosal SerpineE1 concentration and the disease activity (p>0.1, sensitivity=72%, specificity=77.8%, accuracy=73.5%). Conclusion These results suggest that serum and mucosal SeprinE1 expression reflects endoscopic activity of IBD. Correlation of SerpinE1expression between the blood and the bowel mucosa would open up new possibilities in non-invasive disease monitoring of IBD.

Download Full-text

Different Activation of TRAF4 and TRAF6 in Inflammatory Bowel Disease

Mediators of Inflammation ◽

10.1155/2013/647936 ◽

2013 ◽

Vol 2013 ◽

pp. 1-8 ◽

Cited By ~ 8

Author(s):

Jun Shen ◽

Yuqi Qiao ◽

Zhihua Ran ◽

Tianrong Wang

Keyword(s):

Inflammatory Bowel Disease ◽

Immune Cells ◽

Bowel Disease ◽

Binding Sites ◽

Tumor Necrosis ◽

Expression Patterns ◽

Tumor Necrosis Factor Receptor ◽

Inflammatory Bowel ◽

Necrosis Factor ◽

Comprehensive Study

In recent years, interests combining the exploration of tumor necrosis factor receptor-associated factor 4 (TRAF4) and TRAF6 in immune cells and transgenic mice are emerging. Although it has been found that TRAF4 and TRAF6 share the same TRAF binding sites, comprehensive study of TRAF4 and TRAF6 in inflammatory bowel disease (IBD) is still lacking. This paper shows similar and different expression patterns of TRAF4 and TRAF6 in patients with IBD. The results indicate that TRAF4 and TRAF6 are overexpressed in IBD. TRAF4 and TRAF6 play different roles in the pathogenesis of IBD. Moreover, TRAF4 may be an indicator of endoscopic disease activity of UC and TRAF6 preactivation can be detected in noninflamed colonic segments.

Download Full-text